1. Home
  2. SRV vs VYGR Comparison

SRV vs VYGR Comparison

Compare SRV & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NXG Cushing Midstream Energy Fund of Beneficial Interest

SRV

NXG Cushing Midstream Energy Fund of Beneficial Interest

HOLD

Current Price

$43.12

Market Cap

188.0M

Sector

Finance

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.90

Market Cap

194.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRV
VYGR
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
188.0M
194.0M
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
SRV
VYGR
Price
$43.12
$3.90
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.00
AVG Volume (30 Days)
59.6K
482.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,135,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$71.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.24
$2.65
52 Week High
$46.40
$5.55

Technical Indicators

Market Signals
Indicator
SRV
VYGR
Relative Strength Index (RSI) 57.45 50.54
Support Level $42.15 $3.73
Resistance Level $44.23 $4.43
Average True Range (ATR) 0.76 0.24
MACD -0.07 0.04
Stochastic Oscillator 33.33 56.88

Price Performance

Historical Comparison
SRV
VYGR

About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest

NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: